HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wellness Market Executive Decisions: Beckham For Pedialyte, 'Gronk' For CBD, Honderd Out At Mary's, Appointments At GB Sciences, Nature's Bounty

Executive Summary

Cleveland Browns' Beckham promotes Pedialyte for all; Pfizer consumer execTahiri heads Nature 's Bounty international business;GB Sciences adds cannabis operations expert; Honderd steps away at Mary's Brands; and 'Gronk' invests in CBD product firm, begins product development.

You may also be interested in...



COVID Who? CBD Leader Charlotte’s Web Maintains FY 2020 Guidance Of Growth Up To 20%

Charlotte’s Web is strengthening its DTC lead while growing its brick-and-mortar retail business, accelerating its pet product distribution and working to close its Abacus Health acquisition announced in March. The Boulder, CO-based CBD product manufacturer posted a 1% decline in net sales for the first quarter, but expects a rapid escalation in the second half of the year.

With Another Warning, FDA Pledges Report On CBD Use In Non-drug Products

CBD claim warning comes as FDA reviews more than 4,200 comments on its initiative to determine whether to open regulatory paths for firms to market non-drug products containing hemp- or cannabis-derived ingredients. From Deputy Commissioner Abernethy statement included in announcement about warning, it appears agency is getting message industry trade groups stated in comments that enforcement over non-drug products containing CBD cannot wait.

Sturman Leads Nature's Bounty For New Owner: Health And Wellness Industry News

Consumer health product industry veteran executive Paul Sturman takes the helm at Nature's Bounty Co. on the day that private equity firm Kohlberg Kravis Roberts & Co. LP closed its acquisition of a controlling interest in the nutritional and health and wellness product manufacturer from Carlyle Group LP. The Ronkonkoma, N.Y.-based firm on Sept. 28 said Sturman has more than 30 years of experience in the sector, including leading Pfizer Inc.'s consumer product group and is a past chairman of the Consumer Healthcare Products Association. (Also see "KKR Steers Nature's Bounty With Carlyle In Back Seat After Seven-Year Ride" - HBW Insight, 24 Jul, 2017.) Sturman succeeds Steve Cahillane, the second CEO Carlyle appointed in 2014 after acquiring Nature's Bounty, then NBTY Inc., in 2010 and taking the firm private. (Also see "Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane" - Pink Sheet, 20 Aug, 2014.)

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel